European Vaccine Initiative e.V.

Assessing multi-stage malaria vaccines: New clinical trials begin in Burkina Faso Now, the University of Oxford, the Clinical Research Unit of Nanoro and EVI have launched two new clinical trials to test a next‑generation multi-stage malaria vaccine designed to target two stages to...

Two clinical trials are underway to test a next-generation multi-stage malaria vaccine targeting two stages of P. falciparum life cycle for broader protection. 💉🦠

Led by an international consortium, EVI, University of Oxford @ox.ac.uk & IRSS-URCN.🌍

Read more: www.euvaccine.eu/post/assessi...

Our researchers reflect on:
💡 Why they chose a career in science
🌍 How women influence what research is conducted, and how
🚀 Why diversity drives stronger, more impactful research

International Day of Women and Girls in Science 2026: Advancing equity for better research and health outcomes Advancing gender equality in science is not only a matter of fairness, but it also directly improves public health, social policy, and innovation by embedding inclusion into how knowledge is produced ...

🔬 International Day of Women and Girls in Science 2026 ✨Women continue to shape science. At EVI we know gender equality in STEM isn’t just representation, it strengthens research. Today we celebrate EVI’s women scientists & their voices💡🌍

🔗 www.euvaccine.eu/post/interna...
#WomenInScience #IDWGS

EVI supports first-in-human clinical trial of novel Nipah virus vaccine In recent weeks, health authorities in India’s state of West Bengal have confirmed cases of Nipah virus infection amid ongoing surveillance and containment efforts.

EVI is supporting first-in-human trial set to start in April in Belgium, of a promising #NipahVirus vaccine developed by the University of Tokyo. With mortality rates up to 75% and recent cases in India, preparedness matters. 🎯💉

Read more ➡️ www.euvaccine.eu/post/evi-sup...

A 4-dose RTS,S malaria vaccine schedule provides higher protection against severe malaria than a 3-dose schedule. The MVPE-CC consortium contributed key evidence reviewed in a joint session of the WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) and Malaria Policy Advisory Group (MPAG) held in Sep...

🦟💉 New findings show that a 4-dose RTS,S malaria vaccine schedule provides stronger protection against severe malaria. Evidence from MVPE-CC case-control studies, reviewed by WHO advisory groups (SAGE & MPAG), informed guidance published in Dec 2025.

🎯 www.euvaccine.eu/post/a-4-dos...

💉⚗️"Vaccines are technically challenging to manufacture."

@ihieurope.bsky.social spotlights #Inno4vac's efforts in building digital tools (e.g. mathematical models, digital twins & open-source integrative platforms), to reduce #vaccine manufacturing time.

📃 www.ihi.europa.eu/news-events/...

Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK Controlled human infection models (CHIMs) are a critical tool for the understanding of infectious disease progression, characterising immune responses to infection and rapid assessment of vaccines or...

🎉1,000+ views & counting!🎉

Curious about controlled human #Influenza virus infection models strain selection, immune assays, and their role in advancing #vaccine development?

📖Take a moment to read #Inno4vac workshop report➡️ doi.org/10.1111/irv....

#ViewsMilestone #CHIMs @ihieurope.bsky.social

Funded by EDCTP2 @globalhealthedctp3.bsky.social; study conducted by Kintampo Health Research Centre; @kemriwellcome.bsky.social; African Research Collaboration for Health Limited ARCH; Kamuzu University of Health Sciences; @pathmalaria.bsky.social; @lshtm.bsky.social; & @europevaccine.bsky.social

How do we know vaccines work in real life?💉🌍MVPE-CC project partners across Africa and Europe collected real-world evidence on the effectiveness and safety of malaria vaccines, ensuring that data drives decisions and every dose makes a difference.

🎥 youtu.be/kC9KCqVthZc

📢 New vacancy (German required)!

Wir stellen ein: Bilanzbuchhalter (m/w/d)
📍 Heidelberg | 🏠 Hybrid möglich
Erfahrung in Finanzbuchhaltung, SAP, HGB/IFRS? Werde Teil unseres internationalen Non-Profit-Teams und unterstütze die globale Impfstoffentwicklung.

📩 Jetzt bewerben www.euvaccine.eu/careers

What can we learn from case-control studies? with Africa's map on backgrounf with Ghana, Kenya and Malawi highlighted

📊 Case-control studies across Africa are helping researchers understand how malaria vaccines work in real-world settings,
This work, led through the MVPE-CC project, turns data into evidence and evidence into life-saving actions. 🌍

🎥 youtu.be/kC9KCqVthZc

Funded by EDCTP2 @globalhealthedctp3.bsky.social; study conducted by Kintampo Health Research Centre; @kemriwellcome.bsky.social; African Research Collaboration for Health Limited ARCH; Kamuzu University of Health Sciences; @pathmalaria.bsky.social; @lshtm.bsky.social; & @europevaccine.bsky.social

Case-control studies across Africa bring together researchers, ministries of health, health workers & communities to gather real-world data. This teamwork helps refine how #malaria vaccines are rolled out, ensuring stronger protection for those who need it most.🌍

🎥 youtu.be/t-km8MqyQbI

🚨TRANSVAC Academy: Open call!🚨

Work in vaccine R&D? Join expert-led, hands-on training in Animal Welfare & In vivo Imaging.

Why apply?
💡Leading instructors
🤝Network w/ experts
🌍 @cepi.net-funded scholarships for LMIC applicants

📅Apply now: transvac.org
#TRANSVACAcademy

Funded by EDCTP2 @globalhealthedctp3.bsky.social; study conducted by Kintampo Health Research Centre;
@kemriwellcome.bsky.social; African Research Collaboration for Health Limited ARCH; Kamuzu University of Health Sciences; @pathmalaria.bsky.social; @lshtm.bsky.social & @europevaccine.bsky.social

Black and white hand holdong a vial of malaria vaccine, with the following quote above: “People didn’t think in their lifetime they would see a Malaria Vaccine, but we now have two.” - Dr Rafiq Okine, World Health Organization

The rollout of RTS,S and R21 vaccines is a historic step against malaria 🌍💉but the work continues. Real-world data, including case-control studies, is essential to confirm safety, measure effectiveness, & optimise dosing for maximum impact.

🎥 Learn more about CC studies: youtu.be/kC9KCqVthZc

Combating Antimicrobial Resistance: Untapped mAb Potential The PrIMAVeRa project develops a platform to evaluate how mAbs can combat AMR by reducing antibiotic use and providing strategies for policymakers.

EVI-led #PrIMAVeRa_AMR project has published an article on BioProcess International on the use of monoclonal antibodies to tackle #AMR, & how PrIMAVeRa's open-access digital platform can support evidence-based public health decisions.

📃 www.bioprocessintl.com/monoclonal-a...
@ihieurope.bsky.social

Funded by EDCTP2 @globalhealthedctp3.bsky.social; study conducted by Kintampo Health Research Centre;
@kemriwellcome.bsky.social; African Research Collaboration for Health Limited ARCH; Kamuzu University of Health Sciences; @pathmalaria.bsky.social; @lshtm.bsky.social & @europevaccine.bsky.social

Proving the value of malaria vaccines: How case-control studies can guide immunisation strategies YouTube video by European Vaccine Initiative

🩺Cases: people with the disease
💪Controls: similar people without it

Researchers compare exposure to a certain factor, e.g. vaccination & assess protection in real-world settings.

🔍 Fast & powerful, these studies provide vital evidence to guide life-saving policies.

🎥 youtu.be/kC9KCqVthZc

Funded by EDCTP2 @globalhealthedctp3.bsky.social; the study was conducted by Kintampo Health Research Centre (KHRC); @kemriwellcome.bsky.social; University of Malawi - UNIMA; Kamuzu University of Health Sciences; @pathmalaria.bsky.social; @lshtm.bsky.social and @europevaccine.bsky.social

Funded by EDCTP2 @globalhealthedctp3.bsky.social; the study was conducted by Kintampo Health Research Centre (KHRC); @kemriwellcome.bsky.social; University of Malawi - UNIMA; Kamuzu University of Health Sciences; @path.org ; @lshtm.bsky.social and @europevaccine.bsky.social

Proving the value of malaria vaccines: How case-control studies can guide immunisation strategies YouTube video by European Vaccine Initiative

Case-control studies help us understand how vaccines work at the individual level in the real world.🌍Insights from CC studies in Ghana, Kenya & Malawi are guiding immunisation programmes & informing public health policy.

💡Evidence in action, turning data into protection

youtu.be/kC9KCqVthZc?...

Global consortium launched to develop next-generation malaria vaccine EVI is committed to supporting a development pathway that ensures the highest scientific standards from early optimisation through to field evaluation

We are delighted to announce the 2nd Generation #Malaria Vaccine Consortium, a new global partnership created to accelerate malaria vaccine development, co-led by @paediatrics.ox.ac.uk & IRSS/CRUN in Burkina Faso.

➡️ www.euvaccine.eu/post/global-...
#MalariaVaccine #GlobalHealth #Vaccines

Placental Malaria remains a major threat to mothers and newborns, new EVI study shows This comprehensive analysis brings renewed attention to placental malaria (PM), a condition that continues to threaten millions of pregnant women and newborns globally. Drawing on 50 studies conducted...

A new EVI-led systematic review shows that nearly 1 in 5 pregnant women are affected by placental #malaria, in endemic regions, rising to almost 1 in 4 when using more sensitive methods. This work reflects EVI’s 20+ year commitment to advancing vaccine R&D for PM.

www.euvaccine.eu/post/placent...

Boosting global vaccinology capacity: EVI leads vaccinology workshop with MMVC Partners A two-day translational vaccinology workshop was hosted by EVI and the MRCG. The event was attended by 20 participants from MRCG and 8 from the University of Sierra Leone (USL), as part of the MMVC pr...

EVI co-hosted a 2-day translational vaccinology workshop with @mrcunitgambia.bsky.social as part of #MMVC, to strengthen skills in vaccine R&D & clinical trials 💉🩺

EVI led sessions on development, clinical trials & practical research.

Read more⬇️
www.euvaccine.eu/post/boostin...

Advancing global clinical research partnerships: EVI attends LSHTM Annual Trials Day 2025 and Visits MRC Gambia Clinical Sites EVI’s involvement underscored our commitment to strengthening vaccine research capacity, fostering collaboration across diverse research hubs, and sharing our expertise in trial delivery.

Great to join the 3rd Annual Trials’ Day hosted by @mrcunitgambia.bsky.social, discussing challenges and innovation in clinical trial design & delivery. 👩🏽‍🔬👨🏽‍🔬🩺💉

EVI shared perspectives on strengthening partnerships with African research centres ⬇️ www.euvaccine.eu/post/advanci...
#lshtmtrialsday

🚀 We’re Hiring!
EVI is seeking a Project Management Assistant to support international projects in vaccine R&D and #AMR.

🎯Read full job description and apply ➡️ www.euvaccine.eu/careers

Join our diverse, international non-profit team working to advance global health.

Ten years of excellence: Celebrating a decade of the fellowship programme at the European Vaccine Initiative Since welcoming the first fellow in 2015, EVI has supported early- and mid-career researchers from low- and middle-income countries in developing their skills across the vaccine development spectrum.

For 10 years, EVI’s fellowship programme has trained scientists from across Africa & beyond, building skills, leadership & lasting collaborations in #vaccine research 💉

Special thanks to @who.int-TDR & EDCTP @globalhealthedctp3.bsky.social

Learn more ⬇️ www.euvaccine.eu/post/ten-yea...